- Home
- BDRX vs ONFO Comparison
BDRX vs ONFO Comparison
Compare BDRX & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- ONFO
- Stock Information
- Founded
- BDRX 2000
- ONFO 2018
- Country
- BDRX United Kingdom
- ONFO United States
- Employees
- BDRX N/A
- ONFO N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- BDRX Health Care
- ONFO Technology
- Exchange
- BDRX Nasdaq
- ONFO Nasdaq
- Market Cap
- BDRX 5.8M
- ONFO 5.8M
- IPO Year
- BDRX N/A
- ONFO 2022
- Fundamental
- Price
- BDRX $0.90
- ONFO $0.96
- Analyst Decision
- BDRX
- ONFO
- Analyst Count
- BDRX 0
- ONFO 0
- Target Price
- BDRX N/A
- ONFO N/A
- AVG Volume (30 Days)
- BDRX 3.2M
- ONFO 114.4K
- Earning Date
- BDRX 04-11-2025
- ONFO 08-13-2025
- Dividend Yield
- BDRX N/A
- ONFO N/A
- EPS Growth
- BDRX N/A
- ONFO N/A
- EPS
- BDRX N/A
- ONFO N/A
- Revenue
- BDRX N/A
- ONFO $9,087,118.00
- Revenue This Year
- BDRX N/A
- ONFO N/A
- Revenue Next Year
- BDRX N/A
- ONFO N/A
- P/E Ratio
- BDRX N/A
- ONFO N/A
- Revenue Growth
- BDRX N/A
- ONFO 65.97
- 52 Week Low
- BDRX $0.78
- ONFO $0.61
- 52 Week High
- BDRX $41.50
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- BDRX 39.25
- ONFO 45.29
- Support Level
- BDRX $0.85
- ONFO $0.87
- Resistance Level
- BDRX $0.97
- ONFO $1.48
- Average True Range (ATR)
- BDRX 0.11
- ONFO 0.11
- MACD
- BDRX -0.00
- ONFO -0.00
- Stochastic Oscillator
- BDRX 28.24
- ONFO 13.11
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.